StockMacro
Menu

TriSalus Life Sciences

$2.32 -28% in 6 monthsMarket cap $143.1M

TLSI on XNAS, Health Care, TriSalus Life Sciences, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 53% in a year while short interest reached 6.9 times last year's level and revenue rose 15%.

  • BadNet loss $26.3M and free cash outflow $24.7M over 12 months
  • GoodInsiders bought $294K across 3 insiders in 90 days

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
102
Website
trisaluslifesci.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $12.9M, net loss $8.9M.
Quarter to 31 Dec 2021: revenue –, net income $2.9MQuarter to 31 Mar 2022: revenue –, net income $2.8MQuarter to 30 Jun 2022: revenue –, net income $2.4MQuarter to 30 Sep 2022: revenue $3.9M, net income $659KQuarter to 30 Sep 2022: revenue $3.9M, net income $659KQuarter to 31 Dec 2022: revenue $3.2M, net income -$343KQuarter to 31 Dec 2022: revenue $3.2M, net income -$343KQuarter to 31 Mar 2023: revenue $3.0M, net income -$448KQuarter to 31 Mar 2023: revenue $3.0M, net income -$448KQuarter to 30 Jun 2023: revenue $4.6M, net income -$995KQuarter to 30 Jun 2023: revenue $4.6M, net income -$995KQuarter to 30 Sep 2023: revenue $5.2M, net income -$1.3MQuarter to 30 Sep 2023: revenue $5.2M, net income -$1.3MQuarter to 31 Dec 2023: revenue $5.7M, net income –Quarter to 31 Mar 2024: revenue $6.5M, net income -$13.2MQuarter to 31 Mar 2024: revenue $6.5M, net income -$13.2MQuarter to 30 Jun 2024: revenue $7.4M, net income -$4.3MQuarter to 30 Jun 2024: revenue $7.4M, net income -$4.3MQuarter to 30 Sep 2024: revenue $7.3M, net income -$2.4MQuarter to 30 Sep 2024: revenue $7.3M, net income -$2.4MQuarter to 31 Dec 2024: revenue $8.3M, net income –Quarter to 31 Mar 2025: revenue $9.2M, net income -$10.4MQuarter to 31 Mar 2025: revenue $9.2M, net income -$10.4MQuarter to 30 Jun 2025: revenue $11.2M, net income -$8.3MQuarter to 30 Jun 2025: revenue $11.2M, net income -$8.3MQuarter to 30 Sep 2025: revenue $11.6M, net income -$10.8MQuarter to 30 Sep 2025: revenue $11.6M, net income -$10.8MQuarter to 31 Dec 2025: revenue $13.2M, net income -$9.8MQuarter to 31 Dec 2025: revenue $13.2M, net income -$9.8MQuarter to 31 Mar 2026: revenue $8.9M, net income $1.5MQuarter to 31 Mar 2026: revenue $8.9M, net income $1.5MQuarter to 30 Jun 2026: revenue $11.4M, net income -$9.2MQuarter to 30 Jun 2026: revenue $11.4M, net income -$9.2MQuarter to 30 Sep 2026: revenue $12.9M, net income -$8.9MQuarter to 30 Sep 2026: revenue $12.9M, net income -$8.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $13.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$12.9M-$8.9M
30 Jun 2026$11.4M-$9.2M
31 Mar 2026$8.9M$1.5M
31 Dec 2025$13.2M-$9.8M
30 Sep 2025$11.6M-$10.8M
30 Jun 2025$11.2M-$8.3M
31 Mar 2025$9.2M-$10.4M
31 Dec 2024$8.3M–
30 Sep 2024$7.3M-$2.4M
30 Jun 2024$7.4M-$4.3M
31 Mar 2024$6.5M-$13.2M
31 Dec 2023$5.7M–
30 Sep 2023$5.2M-$1.3M
30 Jun 2023$4.6M-$995K
31 Mar 2023$3.0M-$448K
31 Dec 2022$3.2M-$343K
30 Sep 2022$3.9M$659K
30 Jun 2022–$2.4M
31 Mar 2022–$2.8M
31 Dec 2021–$2.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $46.4M $40.2M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +15% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$26.3M -$39.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.40 -$2.00
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 86.5% 84.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -63.0% -77.7% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -56.6% -98.4% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$24.7M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $41.1M $22.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $32.4M $32.8M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$8.7M (net cash) $10.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 47.6 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.01
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.1 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.9 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 211 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
TriSalus Life SciencesTLSI (this company) $143.1Mloss3.1+15%-56.6%
KORU Medical SystemsKRMD $138.4Mloss3.0+18%-1.8%
Newegg CommerceNEGG $167.8Mloss0.12+17%-0.3%
NeuroneticsSTIM $120.6Mloss0.61+23%-14.4%
Anika TherapeuticsANIK $177.2Mloss1.4+9.4%-1.4%
PulmonxLUNG $111.9Mloss1.3-3.2%-47.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$289K

bought $294K, sold $5K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

78 13F filers vs 78

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

36%

22.1M shares held by 13F filers (30 Sep 2026) of 61.7M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.4%

3.3M shares sold short (30 Oct 2026) of 61.7M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

28.4

3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-3.8%

3.4M shares sold short in the report before, 3.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

58%

58% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+11%

$12.9M vs $11.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$360K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.5×

19 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Insider buying $294K, 3 insiders
  • Short interest 3.8M, 6.9× a year earlier

Price $2.32 on 20 Nov 2026, -53% over 12 months (12-month range $2.17 to $7.50)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $3.8M in the last 12 months (the 12 months before: $432K).
Revenue per quarter. Revenue $12.9M in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $90K in the latest quarter, -58% on a year earlier.
Institutional holders (13F filers). 78 13F filers reported holding it in the latest 13F quarter, +50% on a year earlier.
Lobbying spend. Lobbying spend: $360K published in the last 12 months, 0% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Nov 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 294K)
15 Sep 2026Sharp changeShort interest spike: short interest spike, 3.7M vs usual 1.2M (2026-08-31); 8.1x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.1M (2026-08-14); 6.9x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.1M (2026-07-31); 6.5x the same period a year earlier
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 9 (2026-03-31); 2.1x the same period a year earlier
29 Apr 20268-K and other filingsDirector or officer change
7 Apr 20268-K and other filingsDirector or officer change
24 Feb 2026Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 1.8M)
9 Feb 20268-K and other filingsDirector or officer change
9 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 795K vs usual 132K (2025-12-15); 13.8x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 755K vs usual 126K (2025-11-28); 16.1x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 637K vs usual 124K (2025-11-14); 20.0x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 643K vs usual 121K (2025-10-31); 11.0x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 730K vs usual 114K (2025-10-15); 11.8x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 918K vs usual 96K (2025-09-30); 17.9x the same period a year earlier
1 Oct 20258-K and other filingsDirector or officer change
30 Sep 2025Sharp changeShort interest spike: short interest spike, 515K vs usual 83K (2025-09-15); 16.4x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 553K vs usual 68K (2025-08-15); 13.5x the same period a year earlier
29 Aug 20258-K and other filingsDirector or officer change
29 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Aug 2025Sharp changeShort interest spike: short interest spike, 583K vs usual 60K (2025-07-31); 13.6x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 605K vs usual 58K (2025-07-15); 11.6x the same period a year earlier
30 May 20258-K and other filingsDirector or officer change
8 May 20258-K and other filingsPrivate placement of securities (Form D)
23 Apr 20258-K and other filingsDirector or officer change
17 Apr 20258-K and other filingsDirector or officer change
28 Mar 20258-K and other filingsReport will be filed late
25 Feb 20258-K and other filingsDirector or officer change
31 Jan 20258-K and other filingsDirector or officer change
30 Jan 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 337K)
8 Jan 20258-K and other filingsDirector or officer change
30 Dec 20248-K and other filingsPrivate placement of securities (Form D)
1 Nov 20248-K and other filingsDirector or officer change
1 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Oct 2024Sharp changeLobbying on a new issue: lobbying on a new issue: VET (2024-09-30)
21 Oct 2024Lobbying filinglobbying engagement terminated (ALSTON & BIRD LLP)
14 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
7 May 20248-K and other filingsDirector or officer change
7 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Apr 20248-K and other filingsChanged its auditor
2 Apr 20248-K and other filingsReport will be filed late
25 Jan 20248-K and other filingsDirector or officer change
25 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Dec 20238-K and other filingsRegistered new securities for sale (S-1)
15 Dec 20238-K and other filingsRegistered new securities for sale (S-1)
23 Oct 2023Lobbying filinglobbying engagement terminated (COMMONWEALTH POLICY SOLUTIONS)
19 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
1 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
31 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
16 Aug 20238-K and other filingsCompleted an acquisition or asset sale
16 Aug 20238-K and other filingsChanged its auditor
16 Aug 20238-K and other filingsDirector or officer change
16 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jul 20238-K and other filingsA major agreement ended
22 Jun 20238-K and other filingsPrivate placement of securities (Form D)
21 Jun 20238-K and other filingsDelisting notice or listing transfer
24 Jan 2023Sharp changeLobbying spend jump: lobbying spend jump, 140K vs usual 25K (2022-12-31); 7.0x the same period a year earlier
25 Oct 2022Sharp changeLobbying spend jump: lobbying spend jump, 140K vs usual 25K (2022-09-30)
13 Apr 2022Lobbying filingnew lobbying registration (CAPITOL HILL CONSULTING GROUP)
10 Mar 20228-K and other filingsA major agreement ended
7 Mar 20228-K and other filingsDirector or officer change
23 Feb 20228-K and other filingsDirector or officer change
23 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Dec 2021Lobbying filingnew lobbying registration (ALSTON & BIRD LLP)
10 Dec 20218-K and other filingsEarlier financial statements can no longer be relied on
Insider net buying (open market)
Month from 1 Sep 2024: $100K published
Month from 1 Nov 2024: $70K published
Month from 1 Dec 2024: $138K published
Month from 1 Jan 2025: $337K published
Month from 1 Feb 2025: $86K published
Month from 1 May 2025: -$129K published
Month from 1 Feb 2026: $1.8M published
Month from 1 Mar 2026: -$134K published
Month from 1 May 2026: $1.8M published
Month from 1 Oct 2026: -$4K published
Month from 1 Nov 2026: $293K published
Revenue per quarter
Quarter ended 30 Sep 2022: $3.9M; public on 15 Nov 2023
Quarter ended 31 Dec 2022: $3.2M; public on 12 Apr 2024
Quarter ended 31 Mar 2023: $3.0M; public on 16 May 2024
Quarter ended 30 Jun 2023: $4.6M; public on 15 Aug 2024
Quarter ended 30 Sep 2023: $5.2M, +32% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $5.7M, +77% on a year earlier; public on 12 Apr 2024
Quarter ended 31 Mar 2024: $6.5M, +116% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $7.4M, +60% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $7.3M, +42% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $8.3M, +44% on a year earlier; public on 16 Apr 2025
Quarter ended 31 Mar 2025: $9.2M, +42% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $11.2M, +52% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $11.6M, +57% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $13.2M, +60% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $8.9M, -2.9% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $11.4M, +1.7% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $12.9M, +11% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2022: $204K; public on 12 Apr 2024
Quarter ended 31 Mar 2023: $7K; public on 16 May 2024
Quarter ended 30 Jun 2023: $31K; public on 15 Aug 2024
Quarter ended 30 Sep 2023: $178K; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $66K, +843% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $60K, +94% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $169K, -5.1% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $50K; public on 16 Apr 2025
Quarter ended 31 Mar 2025: $754K, +1042% on a year earlier; public on 16 May 2025
Quarter ended 30 Sep 2025: $216K, +28% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $41K, -18% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $141K, -81% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $82K; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $90K, -58% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
30 Sep 2023 report: 8; public on 14 Nov 2023
31 Dec 2023 report: 18; public on 14 Feb 2024
31 Mar 2024 report: 25; public on 15 May 2024
30 Jun 2024 report: 26; public on 14 Aug 2024
30 Sep 2024 report: 29; public on 14 Nov 2024
31 Dec 2024 report: 25; public on 14 Feb 2025
31 Mar 2025 report: 34; public on 15 May 2025
30 Jun 2025 report: 45; public on 14 Aug 2025
30 Sep 2025 report: 52; public on 14 Nov 2025
31 Dec 2025 report: 61; public on 17 Feb 2026
31 Mar 2026 report: 78; public on 15 May 2026
30 Jun 2026 report: 78; public on 14 Aug 2026
30 Sep 2026 report: 78; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $140K published
Quarter from 1 Jan 2023: $140K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $80K published
Quarter from 1 Oct 2023: $90K published
Quarter from 1 Jan 2024: $140K published
Quarter from 1 Apr 2024: $90K published
Quarter from 1 Jul 2024: $120K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $90K published
Quarter from 1 Apr 2025: $90K published
Quarter from 1 Jul 2025: $90K published
Quarter from 1 Oct 2025: $90K published
Quarter from 1 Jan 2026: $90K published
Quarter from 1 Apr 2026: $90K published
Quarter from 1 Jul 2026: $90K published
Quarter from 1 Oct 2026: $90K published

What is unusual now

  • Made public in the last 90 days: it had 3 insiders buy $294K of its shares on the open market within 30 days (3 filings); it also had 3.8M shares sold short in the 14 Aug 2026 report, 6.9× the same report last year. 3 sharp changes in all.
  • Short interest spike: had 3.8M shares sold short in the 31 Jul 2026 report, 6.5× the same report last year Public on 12 Aug 2026.
  • Clustered insider buying: had 3 insiders buy $294K of its shares on the open market within 30 days (3 filings) Public on 19 Nov 2026.
  • Revenue per quarter: Revenue $12.9M in the latest quarter, +11% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 40 insider trades

Last 90 days: 4 sales, $5K; 3 purchases, $294K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Mary T SzelaCEO and PresidentBuy65,192$2.46$160KForm 4
19 Nov 2026Gary B. GordonDirectorBuy10,000$2.20$22KForm 4
17 Nov 2026Richard MarshakChief Commercial OfficerSell544$2.43$1KForm 4
16 Nov 2026Mats WahlstromDirectorBuy50,000$2.24$112KForm 4
7 Oct 2026Bryan F. CoxChief of ResearchSell296$4.39$1KForm 4
7 Oct 2026Richard MarshakChief Commercial OfficerSell325$4.39$1KForm 4
7 Oct 2026Jennifer StevensChief Regulatory OfficerSell316$4.39$1KForm 4
19 May 2026Richard MarshakChief Commercial OfficerSell543$2.67$1KForm 4

78 institutions reported shares at the end of Q3 2026, 36% of the shares outstanding; 9 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
First Light Asset Management, LLC7.4M12.0%$32.0M+864K+13%
BlackRock, Inc.2.6M4.23%$11.3M-48K-1.8%
Vanguard Capital Management LLC1.7M2.79%$7.4M-8,714-0.5%
Cerity Partners LLC1.6M2.60%$6.9M+1,876+0.1%
Geode Capital Management, LLC1.1M1.82%$4.8M-67K-5.6%
Gilder Gagnon Howe & Co LLC819K1.33%$3.5M-31K-3.7%
State Street Corp669K1.08%$2.9M+58K+9.5%
Kennedy Capital Management LLC626K1.01%$2.7M+149K+31%
Thompson Siegel & Walmsley LLC530K0.86%-7,000-1.3%
Nantahala Capital Management, LLC500K0.81%$2.2M-1.5M-75%

Company events

All 63 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Apr 2026Director or officer change8-K
7 Apr 2026Director or officer change8-K
20 Feb 2026Signed a major agreement8-K
9 Feb 2026Director or officer change8-K
1 Oct 2025Director or officer change8-K
29 Aug 2025Director or officer change8-K
30 May 2025Director or officer change8-K
8 May 2025Private placement of securities (Form D)$22.0M sold of $22.0M offeredD

Reported lobbying spend: $90K in Q3 2026, $90K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Sep 2024EndedAlston & Bird LLPfor Trisalus Life SciencesIssues related to Medicare reimbursement.; Issues related to medicare coverage and reimbursement.Health issues, Medicare/Medicaid, VETFiling
1 Jul 2023EndedCommonwealth Policy Solutionsfor Trisalus Life SciencesMedicare and Medicaid rare disease; Medicare and Medicaid rare diseasesMED, Health issues, Medicare/MedicaidFiling
6 Dec 2021NewCapitol Hill Consulting Groupfor Trisalus Life SciencesMedicare and Medicaid reimbursement issues.Medicare/MedicaidFiling
1 Dec 2021NewAlston & Bird LLPfor Trisalus Life SciencesFederal health program requirements and reimbursementMedicare/Medicaid, Health issuesFiling
15 Aug 2018NewCommonwealth Policy Solutionsfor Trisalus Life SciencesMedical device development for oncology, drug delivery for oncologyMedicare/Medicaid, MED, Health issuesFiling

The 5 newest of 112 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Insiders change

    had 3 insiders buy $294K of its shares on the open market within 30 days (3 filings).

    Who bought: Wahlstrom Mats, Gordon Gary B., Szela Mary T.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $294K
    Window
    20 Oct 2026 to 19 Nov 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  2. 19 Nov 2026Insiders record

    Szela Mary T (CEO and President) bought 65,192 shares of TLSI ($160,205)

  3. 19 Nov 2026Insiders record

    Gordon Gary B. (director) bought 10,000 shares of TLSI ($22,000)

  4. 16 Nov 2026Insiders record

    Wahlstrom Mats (director) bought 50,000 shares of TLSI ($112,000)

  5. 11 Sep 2026Short interest and volume change

    had 3.7M shares sold short in the 31 Aug 2026 report, 8.1× the same report last year.

    Same report last year: 457K; its normal report is 1.2M.

    See the evidence
    This period
    3.7M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    437K
    How far from its usual level
    +3.9
    Same report last year
    457K
    History used
    1,112 days
    2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K2025-11-28: 755K2025-12-15: 795K2025-12-31: 1.3M2026-01-15: 1.3M2026-01-30: 1.1M2026-02-13: 1.2M2026-02-27: 987K2026-03-13: 1.1M2026-03-31: 1.2M2026-04-15: 1.3M2026-04-30: 1.4M2026-05-15: 1.7M2026-05-29: 2.1M2026-06-15: 2.2M2026-06-30: 3.1M2026-07-15: 3.6M2026-07-31: 3.8M2026-08-14: 3.8M2026-08-31: 3.7M
    the 31 Aug 2026 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 26 Aug 2026Short interest and volume change

    had 3.8M shares sold short in the 14 Aug 2026 report, 6.9× the same report last year.

    Same report last year: 553K; its normal report is 1.1M.

    See the evidence
    This period
    3.8M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    407K
    How far from its usual level
    +4.4
    Same report last year
    553K
    History used
    1,095 days
    2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K2025-11-28: 755K2025-12-15: 795K2025-12-31: 1.3M2026-01-15: 1.3M2026-01-30: 1.1M2026-02-13: 1.2M2026-02-27: 987K2026-03-13: 1.1M2026-03-31: 1.2M2026-04-15: 1.3M2026-04-30: 1.4M2026-05-15: 1.7M2026-05-29: 2.1M2026-06-15: 2.2M2026-06-30: 3.1M2026-07-15: 3.6M2026-07-31: 3.8M2026-08-14: 3.8M
    the 14 Aug 2026 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 12 Aug 2026Short interest and volume change

    had 3.8M shares sold short in the 31 Jul 2026 report, 6.5× the same report last year.

    Same report last year: 583K; its normal report is 1.1M.

    See the evidence
    This period
    3.8M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    367K
    How far from its usual level
    +4.9
    Same report last year
    583K
    History used
    1,081 days
    2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K2025-11-28: 755K2025-12-15: 795K2025-12-31: 1.3M2026-01-15: 1.3M2026-01-30: 1.1M2026-02-13: 1.2M2026-02-27: 987K2026-03-13: 1.1M2026-03-31: 1.2M2026-04-15: 1.3M2026-04-30: 1.4M2026-05-15: 1.7M2026-05-29: 2.1M2026-06-15: 2.2M2026-06-30: 3.1M2026-07-15: 3.6M2026-07-31: 3.8M
    the 31 Jul 2026 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 19 May 2026Insiders record

    Patience David (Chief Financial Officer) bought 7,100 shares of TLSI ($17,253) (dated 18 May 2026)

  9. 19 May 2026Insiders record

    Wahlstrom Mats (director) bought 60,000 shares of TLSI ($151,800) (dated 18 May 2026)

  10. 19 May 2026Insiders record

    Szela Mary T (CEO and President) bought 39,682 shares of TLSI ($102,776) (dated 18 May 2026)

  11. 19 May 2026Insiders record

    Stansky Michael P (director) bought 610,000 shares of TLSI ($1.5M) (dated 18 May 2026)

  12. 19 May 2026Insiders record

    Gordon Gary B. (director) bought 10,000 shares of TLSI ($24,600) (dated 18 May 2026)

  13. 15 May 2026Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Mar 2026, 2.1× the same quarter last year.

    Same quarter last year: 12; its normal quarter is 9.

    See the evidence
    This period
    25 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    9
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +5.3
    Same quarter last year
    12
    History used
    913 days
    2024-03-31: 92024-06-30: 52024-09-30: 82024-12-31: 12025-03-31: 122025-06-30: 202025-09-30: 92025-12-31: 102026-03-31: 25
    the quarter ended 31 Mar 20268 earlier quartersnormal: 9

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 29 Apr 2026Filings record

    Director or officer change

  15. 7 Apr 2026Filings record

    Director or officer change

  16. 24 Feb 2026Insiders change

    had 5 insiders buy $1.8M of its shares on the open market within 30 days (5 filings).

    Who bought: Patience David, Stansky Michael P, Valle William, Szela Mary T and 1 more.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $1.8M
    Window
    25 Jan 2026 to 24 Feb 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  17. 24 Feb 2026Insiders record

    Gordon Gary B. (director) bought 9,756 shares of TLSI ($40,000) (dated 23 Feb 2026)

  18. 24 Feb 2026Insiders record

    Szela Mary T (CEO and President) bought 30,487 shares of TLSI ($124,997) (dated 23 Feb 2026)

  19. 24 Feb 2026Insiders record

    Valle William (director) bought 30,487 shares of TLSI ($124,997) (dated 23 Feb 2026)

  20. 24 Feb 2026Insiders record

    Stansky Michael P (director) bought 361,098 shares of TLSI ($1.5M) (dated 23 Feb 2026)

  21. 24 Feb 2026Insiders record

    Patience David (Chief Financial Officer) bought 3,657 shares of TLSI ($14,994) (dated 23 Feb 2026)

  22. 9 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 9 Feb 2026Filings record

    Director or officer change

  24. 25 Dec 2025Short interest and volume change

    had 795K shares sold short in the 15 Dec 2025 report, 14× the same report last year.

    Same report last year: 58K; its normal report is 132K.

    See the evidence
    This period
    795K (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    132K
    Typical spread (median absolute deviation)
    103K
    How far from its usual level
    +4.4
    Same report last year
    58K
    History used
    853 days
    2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K2025-11-28: 755K2025-12-15: 795K
    the 15 Dec 2025 report24 earlier reportsnormal: 132K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Dec 2025Short interest and volume change

    had 755K shares sold short in the 28 Nov 2025 report, 16× the same report last year.

    Same report last year: 47K; its normal report is 126K.

    See the evidence
    This period
    755K (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    126K
    Typical spread (median absolute deviation)
    92K
    How far from its usual level
    +4.6
    Same report last year
    47K
    History used
    836 days
    2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K2025-11-28: 755K
    the 28 Nov 2025 report24 earlier reportsnormal: 126K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 26 Nov 2025Short interest and volume change

    had 637K shares sold short in the 14 Nov 2025 report, 20× the same report last year.

    Same report last year: 32K; its normal report is 124K.

    See the evidence
    This period
    637K (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    124K
    Typical spread (median absolute deviation)
    89K
    How far from its usual level
    +3.9
    Same report last year
    32K
    History used
    822 days
    2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K2025-11-14: 637K
    the 14 Nov 2025 report24 earlier reportsnormal: 124K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 13 Nov 2025Short interest and volume change

    had 643K shares sold short in the 31 Oct 2025 report, 11× the same report last year.

    Same report last year: 58K; its normal report is 121K.

    See the evidence
    This period
    643K (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    121K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +4.4
    Same report last year
    58K
    History used
    808 days
    2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K2025-10-31: 643K
    the 31 Oct 2025 report24 earlier reportsnormal: 121K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 25 Oct 2025Short interest and volume change

    had 730K shares sold short in the 15 Oct 2025 report, 12× the same report last year.

    Same report last year: 62K; its normal report is 114K.

    See the evidence
    This period
    730K (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    114K
    Typical spread (median absolute deviation)
    62K
    How far from its usual level
    +6.7
    Same report last year
    62K
    History used
    792 days
    2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K2025-10-15: 730K
    the 15 Oct 2025 report24 earlier reportsnormal: 114K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 Oct 2025Short interest and volume change

    had 918K shares sold short in the 30 Sep 2025 report, 18× the same report last year.

    Same report last year: 51K; its normal report is 96K.

    See the evidence
    This period
    918K (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    96K
    Typical spread (median absolute deviation)
    42K
    How far from its usual level
    +13.1
    Same report last year
    51K
    History used
    777 days
    2024-09-30: 51K2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K2025-09-30: 918K
    the 30 Sep 2025 report24 earlier reportsnormal: 96K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 1 Oct 2025Filings record

    Director or officer change

  31. 25 Sep 2025Short interest and volume change

    had 515K shares sold short in the 15 Sep 2025 report, 16× the same report last year.

    Same report last year: 31K; its normal report is 83K.

    See the evidence
    This period
    515K (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    83K
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +6.8
    Same report last year
    31K
    History used
    762 days
    2024-09-13: 31K2024-09-30: 51K2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K2025-08-29: 457K2025-09-15: 515K
    the 15 Sep 2025 report24 earlier reportsnormal: 83K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 29 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 29 Aug 2025Filings record

    Director or officer change

  34. 27 Aug 2025Short interest and volume change

    had 553K shares sold short in the 15 Aug 2025 report, 13× the same report last year.

    Same report last year: 41K; its normal report is 68K.

    See the evidence
    This period
    553K (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    68K
    Typical spread (median absolute deviation)
    35K
    How far from its usual level
    +9.3
    Same report last year
    41K
    History used
    731 days
    2024-08-15: 41K2024-08-30: 33K2024-09-13: 31K2024-09-30: 51K2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K2025-08-15: 553K
    the 15 Aug 2025 report24 earlier reportsnormal: 68K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 12 Aug 2025Short interest and volume change

    had 583K shares sold short in the 31 Jul 2025 report, 14× the same report last year.

    Same report last year: 43K; its normal report is 60K.

    See the evidence
    This period
    583K (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    60K
    Typical spread (median absolute deviation)
    28K
    How far from its usual level
    +10.5
    Same report last year
    43K
    History used
    716 days
    2024-07-31: 43K2024-08-15: 41K2024-08-30: 33K2024-09-13: 31K2024-09-30: 51K2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K2025-07-31: 583K
    the 31 Jul 2025 report24 earlier reportsnormal: 60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 Jul 2025Short interest and volume change

    had 605K shares sold short in the 15 Jul 2025 report, 12× the same report last year.

    Same report last year: 52K; its normal report is 58K.

    See the evidence
    This period
    605K (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    58K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +10.9
    Same report last year
    52K
    History used
    700 days
    2024-07-15: 52K2024-07-31: 43K2024-08-15: 41K2024-08-30: 33K2024-09-13: 31K2024-09-30: 51K2024-10-15: 62K2024-10-31: 58K2024-11-15: 32K2024-11-29: 47K2024-12-13: 58K2024-12-31: 84K2025-01-15: 83K2025-01-31: 73K2025-02-14: 128K2025-02-28: 136K2025-03-14: 124K2025-03-31: 123K2025-04-15: 26K2025-04-30: 36K2025-05-15: 109K2025-05-30: 33K2025-06-13: 120K2025-06-30: 550K2025-07-15: 605K
    the 15 Jul 2025 report24 earlier reportsnormal: 58K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 30 May 2025Filings record

    Director or officer change

  38. 8 May 2025Filings record

    Private placement of securities (Form D)

  39. 23 Apr 2025Filings record

    Director or officer change

  40. 17 Apr 2025Filings record

    Director or officer change

Showing the newest 40 of 98 entries; narrow the window or the kind of data to see older ones.

Not listed: 101 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001826667
Ticker
TLSI
Domain
trisaluslifesci.com
Hq location
CO|WESTMINSTER|80031 (1 unverified)
Lobbying client
trisalus life sciences
Name
MedTech Acquisition Corp, TriSalus Life Sciences, Inc.
Uei
GM3JQR9KB4F3
  • Federal lobbying disclosures (LDA)5 records, 94 data points15 Aug 2018 to 30 Sep 2026
  • SEC Form 13F institutional holdings117 data points30 Sep 2023 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)126 records30 Nov 2020 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)340 data points10 Sep 2020 to 6 Nov 2026
  • SEC Form 4 insider transactions40 records, 76 data points10 Sep 2024 to 19 Nov 2026
  • FINRA short interest (twice monthly)234 data points15 Aug 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1648 data points11 Aug 2023 to 20 Nov 2026
  • USASpending.gov federal awards6 data points13 Dec 2011 to 17 Feb 2013